Dazodalibep Eases Moderate-to-high Disease Activity in Sjögren’s Patients: Trial Data
The investigational therapy dazodalibep markedly eased disease activity in people with Sjögren’s syndrome with moderate-to-high systemic disease activity, meeting the primary goal of a Phase 2 trial. Ahead of expectations, the therapy’s developer, Horizon Therapeutics, plans to work with the U.S. Food and Drug Administration (FDA) to design…